State Street’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $117M | Buy |
5,412,901
+835,932
| +18% | +$18.1M | ﹤0.01% | 1292 |
|
|
2025
Q4 | $109M | Buy |
4,576,969
+1,182,115
| +35% | +$24.1M | ﹤0.01% | 1304 |
|
|
2025
Q3 | $46.2M | Sell |
3,394,854
-235,961
| -6% | -$2.45M | ﹤0.01% | 1765 |
|
|
2025
Q2 | $29.6M | Sell |
3,630,815
-65,664
| -2% | -$561K | ﹤0.01% | 1968 |
|
|
2025
Q1 | $29M | Buy |
3,696,479
+702,750
| +23% | +$8.15M | ﹤0.01% | 1916 |
|
|
2024
Q4 | $44.6M | Sell |
2,993,729
-17,445
| -0.6% | -$285K | ﹤0.01% | 1773 |
|
|
2024
Q3 | $46M | Sell |
3,011,174
-43,882
| -1% | -$692K | ﹤0.01% | 1747 |
|
|
2024
Q2 | $46.5M | Sell |
3,055,056
-1,849,457
| -38% | -$29.9M | ﹤0.01% | 1717 |
|
|
2024
Q1 | $92.6M | Buy |
4,904,513
+664,936
| +16% | +$11.5M | ﹤0.01% | 1362 |
|
|
2023
Q4 | $81M | Buy |
4,239,577
+39,553
| +0.9% | +$632K | ﹤0.01% | 1432 |
|
|
2023
Q3 | $75.4M | Sell |
4,200,024
-142,224
| -3% | -$2.86M | ﹤0.01% | 1363 |
|
|
2023
Q2 | $88.2M | Sell |
4,342,248
-1,154,005
| -21% | -$22M | ﹤0.01% | 1309 |
|
|
2023
Q1 | $100M | Buy |
5,496,253
+1,951,970
| +55% | +$37.3M | 0.01% | 1187 |
|
|
2022
Q4 | $73.3M | Sell |
3,544,283
-597,777
| -14% | -$16.4M | ﹤0.01% | 1382 |
|
|
2022
Q3 | $108M | Sell |
4,142,060
-293,789
| -7% | -$7.77M | 0.01% | 1065 |
|
|
2022
Q2 | $112M | Buy |
4,435,849
+1,685,930
| +61% | +$41.3M | 0.01% | 1077 |
|
|
2022
Q1 | $86.8M | Buy |
2,749,919
+557,988
| +25% | +$18.7M | ﹤0.01% | 1392 |
|
|
2021
Q4 | $88.7M | Sell |
2,191,931
-139,699
| -6% | -$5.42M | ﹤0.01% | 1390 |
|
|
2021
Q3 | $81.3M | Sell |
2,331,630
-354,071
| -13% | -$11M | ﹤0.01% | 1438 |
|
|
2021
Q2 | $73.7M | Buy |
2,685,701
+520,307
| +24% | +$14.9M | ﹤0.01% | 1548 |
|
|
2021
Q1 | $60.8M | Buy |
2,165,394
+342,539
| +19% | +$11.9M | ﹤0.01% | 1596 |
|
|
2020
Q4 | $47.3M | Sell |
1,822,855
-695,613
| -28% | -$16.8M | ﹤0.01% | 1671 |
|
|
2020
Q3 | $43.2M | Buy |
2,518,468
+930,969
| +59% | +$20.8M | ﹤0.01% | 1569 |
|
|
2020
Q2 | $39.3M | Buy |
1,587,499
+943,962
| +147% | +$25.5M | ﹤0.01% | 1597 |
|
|
2020
Q1 | $8.93M | Buy |
643,537
+3,070
| +0.5% | +$38.2K | ﹤0.01% | 2346 |
|
|
2019
Q4 | $6.47M | Buy |
640,467
+23,221
| +4% | +$195K | ﹤0.01% | 2726 |
|
|
2019
Q3 | $5.62M | Buy |
617,246
+6,133
| +1% | +$49.3K | ﹤0.01% | 2726 |
|
|
2019
Q2 | $4.86M | Buy |
611,113
+69,738
| +13% | +$698K | ﹤0.01% | 2835 |
|
|
2019
Q1 | $6.76M | Buy |
541,375
+31,132
| +6% | +$338K | ﹤0.01% | 2619 |
|
|
2018
Q4 | $5.5M | Buy |
510,243
+420,381
| +468% | +$4.91M | ﹤0.01% | 2672 |
|
|
2018
Q3 | $1.25M | Buy |
89,862
+25,162
| +39% | +$321K | ﹤0.01% | 3368 |
|
|
2018
Q2 | $792K | Buy |
+64,700
| New | +$1.02M | ﹤0.01% | 3424 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
State Street's RCUS Position: Q1 2026 in Review
State Street increased its Arcus Biosciences (RCUS) stake by 18% in Q1 2026, buying an estimated $18.1M and bringing the position to 5,412,901 shares worth $117M. The position accounts for ﹤0.01% of the portfolio, ranked #1292.
State Street first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- State Street held 5,412,901 shares of Arcus Biosciences worth $117M as of Q1 2026.
- State Street bought 835,932 Arcus Biosciences shares in Q1 2026, an estimated $18.1M.
- Arcus Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1292 holding.
- State Street first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.